Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.

Mori S, Crawford BS, Roddy JV, Phillips G, Elder P, Hofmeister CC, Efebera Y, Benson DM Jr.

Hematol Oncol. 2012 Sep;30(3):156-62. doi: 10.1002/hon.1019. Epub 2011 Oct 26.

2.

Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.

Benson DM Jr, Panzner K, Hamadani M, Hofmeister CC, Bakan CE, Smith MK, Elder P, Krugh D, O'Donnell L, Devine SM.

Leuk Lymphoma. 2010 Feb;51(2):243-51. doi: 10.3109/10428190903480728.

3.

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.

van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD Jr, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B.

Blood. 2007 Aug 1;110(3):827-32. Epub 2007 Apr 6.

4.

Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.

Iwama K, Chihara D, Tsuda K, Ugai T, Sugihara H, Nishida Y, Yamakura M, Takeuchi M, Matsue K.

Eur J Haematol. 2013 Feb;90(2):134-41. doi: 10.1111/ejh.12050. Epub 2013 Jan 7.

PMID:
23210517
5.

Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.

García de Veas Silva JL, Bermudo Guitarte C, Menéndez Valladares P, Rojas Noboa JC, Kestler K, Duro Millán R.

PLoS One. 2016 Nov 28;11(11):e0166841. doi: 10.1371/journal.pone.0166841. eCollection 2016.

6.

Best treatment strategies in high-risk multiple myeloma: navigating a gray area.

Bianchi G, Richardson PG, Anderson KC.

J Clin Oncol. 2014 Jul 10;32(20):2125-32. doi: 10.1200/JCO.2014.55.7900. Epub 2014 Jun 2.

PMID:
24888801
7.

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network.

Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9. Erratum in: Lancet. 2011 Nov 26;378(9806):1846.

PMID:
21146205
8.

Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.

Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, Kuroda Y, Chou T, Yoshiki Y, Suzuki K, Murakami H, Hayashi K, Mina R, Palumbo A, Shimizu K; Japanese Society of Myeloma; European Myeloma Network.

Acta Haematol. 2014;132(2):211-9.

PMID:
24662986
9.

Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.

Pendón-Ruiz de Mier MV, Alvarez-Lara MA, Ojeda-López R, Martín-Malo A, Carracedo J, Caballero-Villarraso J, Alonso C, Aljama P.

Nefrologia. 2013 Nov 13;33(6):788-96. doi: 10.3265/Nefrologia.pre2013.Sep.12176. English, Spanish.

10.

Treatment of newly diagnosed myeloma.

Palumbo A, Rajkumar SV.

Leukemia. 2009 Mar;23(3):449-56. doi: 10.1038/leu.2008.325. Epub 2008 Nov 13. Review.

11.

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.

Dejoie T, Attal M, Moreau P, Harousseau JL, Avet-Loiseau H.

Haematologica. 2016 Mar;101(3):356-62. doi: 10.3324/haematol.2015.126797. Epub 2015 Dec 3.

12.

[Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].

Huang B, Li J, Liu J, Gu J, Zheng D, Xu D, Zou W, Wang H.

Zhonghua Nei Ke Za Zhi. 2014 Nov;53(11):865-72. Chinese.

PMID:
25586356
13.

Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.

Hansen CT, Pedersen PT, Nielsen LC, Abildgaard N.

Eur J Haematol. 2014 Nov;93(5):407-13. doi: 10.1111/ejh.12376. Epub 2014 Jun 14.

PMID:
24809596
14.

[Measurement of serum free light chains and its clinical significance in 20 newly diagnosed patients of multiple myeloma].

Mao XB, Chen XQ, Zhai YP, Liang R, Gao GX, Ma GG, Yu YP, Li F.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):829-32. Chinese.

PMID:
18718070
15.

Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.

Xu Y, Sui W, Deng S, An G, Wang Y, Xie Z, Yao H, Zhu G, Zou D, Qi J, Hao M, Zhao Y, Wang J, Chen T, Qiu L.

Leuk Lymphoma. 2013 Jan;54(1):123-32. doi: 10.3109/10428194.2012.704033. Epub 2012 Sep 5.

PMID:
22712834
16.

Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.

Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B.

Clin Lymphoma Myeloma. 2006 Nov;7(3):210-6.

PMID:
17229337
17.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.

J Clin Oncol. 2010 Feb 10;28(5):800-7. doi: 10.1200/JCO.2009.22.7561. Epub 2010 Jan 4. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314.

PMID:
20048187
18.

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.

Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel P, Fonseca R, Vincent Rajkumar S, Keith Stewart A.

Br J Haematol. 2012 Feb;156(3):326-33. doi: 10.1111/j.1365-2141.2011.08949.x. Epub 2011 Nov 23.

PMID:
22107129
19.

Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.

Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):424-430.e1. doi: 10.1016/j.clml.2014.02.003. Epub 2014 Feb 16.

PMID:
24650974
20.

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.

Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, Crippa C, De Rosa L, Pregno P, Grasso M, Liberati AM, Caravita T, Pisani F, Guglielmelli T, Callea V, Musto P, Cangialosi C, Passera R, Boccadoro M, Palumbo A.

J Clin Oncol. 2010 Apr 20;28(12):2077-84. doi: 10.1200/JCO.2009.23.7172. Epub 2010 Mar 22.

PMID:
20308672

Supplemental Content

Support Center